ACM
KYTX icon

Accent Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Accent Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.7K Buy
+545
New +$4.54K ﹤0.01% 288

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Accent Capital Management's KYTX Position: Q1 2026 in Review

Accent Capital Management opened a new position in Kyverna Therapeutics (KYTX) in Q1 2026: 545 shares worth $4.7K. The stake represents ﹤0.01% of the portfolio and ranks #288 among its holdings.

111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Accent Capital Management held 545 shares of Kyverna Therapeutics worth $4.7K as of Q1 2026.
  • Kyverna Therapeutics was a new Accent Capital Management position in Q1 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Accent Capital Management's portfolio in Q1 2026, its #288 holding.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.